{
"id":"mk19_a_np_q055",
"number":55,
"bookId":"np",
"correctAnswer":"D",
"title":"Question 55",
"stimulus":[
{
"type":"p",
"hlId":"2001bc",
"children":[
"A 49-year-old woman is evaluated during a routine follow-up visit. Medical history is significant for chronic kidney disease, hypertension, and HIV infection. She has been taking her current antihypertensive medications for 6 years. Her antiretroviral regimen was changed 6 weeks ago to a more convenient once-daily dosing regimen. Current medications are dolutegravir-abacavir-lamivudine and lisinopril-hydrochlorothiazide."
]
},
{
"type":"p",
"hlId":"6cbba7",
"children":[
"Findings on physical examination, including vital signs, are normal."
]
},
{
"type":"p",
"hlId":"1e316b",
"children":[
"Laboratory studies performed 2 weeks ago showed a continued suppressed viral load and a ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"serum creatinine"
]
},
" level increase from her baseline of 1.2 mg/dL to 1.6 mg/dL (106.1-141.4 µmol/L)."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"01d588",
"children":[
"Today's laboratory studies:"
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f461b2",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Creatinine, serum",
"children":[
"Creatinine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"3a34ea",
"class":"cell text l",
"children":[
"1.6 mg/dL (141.4 µmol/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"747c2a",
"class":"cell text l",
"children":[
"Urinalysis"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"23df03",
"class":"cell text l",
"children":[
"No blood, protein, or erythrocytes"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"58e613",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Albumin-creatinine ratio, urine",
"children":[
"Urine albumin-creatinine ratio"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"6e652f",
"class":"cell text l",
"children":[
"100 mg/g (unchanged from baseline)"
]
}
]
}
]
}
]
}
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"cb2b54",
"children":[
"Which of the following is the most appropriate management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Discontinue lisinopril-hydrochlorothiazide"
}
},
{
"letter":"B",
"text":{
"__html":"Measure 24-hour urine creatinine clearance"
}
},
{
"letter":"C",
"text":{
"__html":"Return to prior antiretroviral regimen"
}
},
{
"letter":"D",
"text":{
"__html":"No further management is indicated"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"96a1f1",
"hvc":true,
"children":[
"Some medications (such as cimetidine, trimethoprim, cobicistat, dolutegravir, and bictegravir) reduce proximal tubule secretion of creatinine, resulting in increases in serum creatinine."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"0dbc26",
"children":[
"No further management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
") is indicated for this patient. Some medications (such as cimetidine, trimethoprim, cobicistat, dolutegravir, and bictegravir) reduce proximal tubule secretion of creatinine, resulting in increases in serum creatinine that are nonprogressive; they do not affect glomerular filtration rate (GFR). This patient's antiretroviral regimen was changed to include dolutegravir 6 weeks earlier. Slight increases in serum creatinine of 0.2 mg/dL to 0.3 mg/dL (17.7-26.5 µmol/L) may occur. This is more pronounced in patients with chronic kidney disease (CKD), in which creatinine secretion contributes proportionately more to creatinine clearance. In patients with CKD who are taking the integrase inhibitors dolutegravir or bictegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine, or the pharmacokinetic enhancer (CYP3A inhibitor) cobicistat, serum creatinine elevations are nonprogressive and will remain stable within 1 to 2 weeks of initiation. Therefore, in the absence of other signs of kidney disease (hematuria, pyuria, or increasing proteinuria), and with a serum creatinine that has remained unchanged since the patient's 4-week assessment, no further evaluation is necessary. In this case, measuring the patient's serum cystatin C level could be a helpful confirmatory test, because the level is not affected by these medications."
]
},
{
"type":"p",
"hlId":"1ba881",
"children":[
"Discontinuation of combined lisinopril-hydrochlorothiazide (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
") is not necessary. This patient has been taking her current antihypertensive combination for 6 years, and it is unlikely to have caused this acute increase in serum creatinine; the hemodynamic effects of ACE inhibitors on glomerular filtration occur within days of initiation."
]
},
{
"type":"p",
"hlId":"d6a8d4",
"children":[
"A 24-hour urine creatinine clearance (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
") will be decreased in this case (due to drug-related lower creatinine secretion) and will not provide additional diagnostic information."
]
},
{
"type":"p",
"hlId":"b2bfef",
"children":[
"Returning to the prior antiretroviral regimen (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
") is not indicated, as the effects of dolutegravir on the patient's serum creatinine level does not indicate GFR decline."
]
}
],
"relatedSection":"mk19_a_np_s1_1_1_1",
"objective":{
"__html":"Identify drugs as a nonglomerular cause of an increase in serum creatinine level."
},
"references":[
[
"Milburn J, Jones R, Levy JB. Renal effects of novel antiretroviral drugs. Nephrol Dial Transplant. 2017;32:434-439. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27190354",
"target":"_blank"
},
"children":[
"PMID: 27190354"
]
},
" doi:10.1093/ndt/gfw064"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":12,
"B":14,
"C":20,
"D":53,
"E":0
},
"hlIds":[
"2001bc",
"6cbba7",
"1e316b",
"01d588",
"f461b2",
"3a34ea",
"747c2a",
"23df03",
"58e613",
"6e652f",
"cb2b54",
"96a1f1",
"0dbc26",
"1ba881",
"d6a8d4",
"b2bfef"
]
}